PT  - JOURNAL ARTICLE
AU  - Braeye, Toon
AU  - van Loenhout, Joris
AU  - Brondeel, Ruben
AU  - Stouten, Veerle
AU  - Hubin, Pierre
AU  - Billuart, Matthieu
AU  - Chung, Jenny
AU  - Vandromme, Mathil
AU  - Wyndham-Thomas, Chloé
AU  - Blot, Koen
AU  - Catteau, Lucy
TI  - COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022
AID  - 10.1101/2022.05.09.22274623
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.09.22274623
4099  - http://medrxiv.org/content/early/2022/05/11/2022.05.09.22274623.short
4100  - http://medrxiv.org/content/early/2022/05/11/2022.05.09.22274623.full
AB  - The COVID-19 vaccination campaign in Belgium aimed to reduce disease spread and severity. We quantified the observed vaccine effectiveness (VE) against symptomatic infection (VEi) and hospitalization (VEh).Exhaustive data on testing and vaccination was combined with a clinical hospital survey. We estimated VEi using a test negative design and VEh using a proportional hazard analysis. We controlled for prior infection, age, sex, province of residence and calendar week of sampling. Variant of concern specific VE-estimates were obtained by time since vaccination from July 2021 to April 2022.We included 1,433,135 persons. VEi against Delta waned from an initial estimate of 81% (95%CI 80- 82) to 56% (95%CI 56-57) 100-150 days after primary-vaccination. Booster-vaccination increased initial VEi to 84% (95%CI 83-85). Against Omicron, an initial VEi of 37% (95%CI 34-40) waned to 18% (95%CI 17-20) 100-150 days after primary-vaccination. Booster-vaccination increased VEi to 52% (95%CI 51-53) and waned to 25% (95%CI 24-27) 100-150 days after vaccination. Hybrid immunity conferred by prior infection and booster-vaccination outperformed booster-vaccination only even if the infection was over one year ago, 67% (95%CI 66-68). Initial VEh for booster-vaccination decreased from 93% (95%CI 93-94) against Delta to 87% (95%CI 85-89) against Omicron. VEh for Omicron waned to 66% (95%CI 63-70) 100-150 days after booster-vaccination.In conclusion, we report significant immune-escape by Omicron. VEh was less affected than VEi and immune-escape was attenuated by booster-vaccination. Waning further reduced VEi- and VEh- estimates. Infection-acquired immunity offered additional protection against symptomatic infection in vaccinated persons which lasted at least one year.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Belgian Federal and Regional Authorities through funding for the LINK-VACC project. The funding source had no role in the study design, collection, analysis, interpretation, writing of the report or deciding to submit the paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data analyses carried out in this work are among the legal tasks of Sciensano (artikel 4.4 Wet tot oprichting van Sciensano; article 4.4 Law establishment Sciensano). Article 4.4 explicitly states that Sciensano is authorized to collect, validate, analyse, report and archive data of a personal nature concerning public health. Sciensano is further authorized to make these processed data available with approval of the qualified sectoral committees. Linkage of hospitalized patient data to vaccination, testing, sequencing and socioeconomic data within the LINK-VACC project was approved by the medical ethics committee Universitair ziekenhuis Brussels-Vrije Universiteit Brussels (UZ-VUB) on 03/02/2021 (reference number 2020/523) and obtained authorization from the Information Security Committee Social Security and Health (reference number IVC/KSZG/21/034). Ethics committee/IRB of Universitair ziekenhuis Brussels-Vrije Universiteit Brussels (UZ-VUB) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPerson-level data is not available, aggregated data from the present study can be obtained from the authors upon reasonable request. https://epistat.wiv-isp.be/covid/